home / stock / opnt / opnt news


OPNT News and Press, Opiant Pharmaceuticals Inc. From 04/23/19

Stock Information

Company Name: Opiant Pharmaceuticals Inc.
Stock Symbol: OPNT
Market: NASDAQ

Menu

OPNT OPNT Quote OPNT Short OPNT News OPNT Articles OPNT Message Board
Get OPNT Alerts

News, Short Squeeze, Breakout and More Instantly...

OPNT - First exec indicted over role in opioid crisis

Laurence Doud III, former CEO of Rochester Drug Co-Operative, was indicted yesterday by a Manhattan federal grand jury on charges of narcotics conspiracy and conspiracy to defraud the Drug Enforcement Administration (DEA) related to the distribution of "tens of millions" of opioid painkill...

OPNT - DOJ charges 31 docs for over-prescribing opioids

The U.S. Depart of Justice has charged 60 people , including 31 physicians, with illegally prescribing and distributing opioid painkillers. The DOJ claims that the group, which includes 53 medical professionals, are tied to ~350K prescriptions and 32M pills. More news on: Endo Internation...

OPNT - Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT003, Nasal Nalmefene, for Treatment of Synthetic Opioid Overdose

SANTA MONICA, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that clinical pharmacokinetic (PK) data for OPNT003, nasal nalmefene containing Intr...

OPNT - Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT002, Nasal Naltrexone, for Treatment of Alcohol Use Disorder

SANTA MONICA, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that clinical pharmacokinetic data of OPNT002, nasal naltrexone containing Intravail...

OPNT - Opiant Pharmaceuticals receives $3M grant for OPNT003

Opiant Pharmaceuticals (NASDAQ: OPNT ) has been awarded the second tranche of $3M from the total grant of ~$7.4M from the National Institutes of Health’s (“NIH”) National Institute on Drug Abuse (“NIDA”) for the development of OPNT003, nasal nalmefen...

OPNT - Opiant Pharmaceuticals Announces Award of Second Tranche of Approximately $3.0 Million from National Institutes of Health Grant for Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose

SANTA MONICA, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, has been awarded the second tranche of $3.0 million from the total grant of approximatel...

OPNT - FDA's Gottlieb proposes higher standard for future opioid approvals

In testimony before a Senate Appropriations Subcommittee about the FDA's 2020 budget request, Commissioner Scott Gottlieb, M.D. emphasized the importance of a relatively paltry additional $55M to continue the agency's work combating the opioid crisis. More news on: Endo International plc...

OPNT - Opiant Pharmaceuticals to Present at 18th Annual Needham Healthcare Conference

SANTA MONICA, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that Roger Crystal, M.D., Opiant’s Chief Executive ...

OPNT - Purdue Pharma settles opioid case in OK for $270M

Privately held Purdue Pharma LP has agreed to pay the state of Oklahoma $270M to settle litigation from the AG's office over its role in the opioid crisis there. More news on: Endo International plc, INSYS Therapeutics, Inc., Titan Pharmaceuticals, Inc., Healthcare stocks news, Stocks on...

OPNT - Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q4 2018 Results - Earnings Call Transcript

Opiant Pharmaceuticals, Inc. (OPNT) Q4 2018 Results Conference Call March 21, 2019 04:30 PM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Dr. Roger Crystal - CEO David O'Toole - CFO Conference Call Participants David Bautz - Zacks Investment Research Prese...

Previous 10 Next 10